Search Results

1 - 10 of 100 items :

Clear All

. Scully M, Yarranton H, Liesner R, et al. Regional UK TTP registry: correlation with laboratory ADAMTS 13 analysis and clinical features. Br J Haematol. 2008;142(5):819-826. 13. Ferrari S, Mudde GC, Rieger M, et al. IgG subclass distribution of anti-ADAMTS13 antibodies in patients with acquired thrombotic thrombocytopenic purpura. J Thromb Haemost. 2009;7(10):1703-1710. 14. Ferrari S, Scheiflinger F, Rieger M, et al. Prognostic value of 614 American Society of Hematology anti- ADAMTS 13 antibody features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult


An advanced control system is considered for wood Thermal Treatment Processing (TTP) in order to cope with the scarcity of on-line measurements as well as cope with a variety of unpredictable operational conditions arising due to disturbances and large uncertainties. The architecture of the proposed control system includes a number of Building Blocks (BB), functionally based on well-established algorithms, so that that the design and operation of the system use mainly parameterisation via simulation, optimization and coordination. In the created BB a set of advances are incorporated: first principle modelling of WEP, inference control, Run-to-Run optimization, Case-Based Reasoning (CBR). Some results of real applications in SMEs are presented.

infarction due to idiopathic thrombotic thrombocytopenic purpura. Diagnostic pathology 2015; 10 : 52. 10. VISAGIE GJ, LOUW VJ. Myocardial injury in HIV-associated thrombotic thrombocytopenic purpura (TTP). Transfusion medicine 2010; 20 : 258-264. 11. PEREZ L, RAMAPPA P, GUZMAN JA. Myocardial injury in thrombotic thrombocytopenic purpura: a frequent, perplexing complication . International journal of cardiology 2008; 128 : 257-260. 12. BRAZELTON J, OSTER RA, MCCLESKEY B, FULLER J, ADAMSKI J, MARQUES MB. Increased troponin I is associated with fatal outcome in

1 Introduction Thrombotic thrombocytopenic purpura (TTP) is clinically characterized by the occurrence of thrombocytopenia and microangiopathic hemolytic anemia [ 1 , 2 , 3 ]. TTP was first described as a pathological entity in 1924 by Moschcowitz [ 1 ] and was clearly identified as an autoimmune disorder by Harrington et al. in 1951 [ 4 ]. Currently, after 70 years, we know that the majority of TTP patients suffer from acquired TTP caused by the presence of autoantibodies (AAbs) against ADAMTS13 [ 5 , 6 , 7 ], a protease that cleaves the von Willebrand

Blood culture remains the gold standard for diagnosis of bloodstream infection. Time to blood culture positivity (TTP) depends upon the type of bacteria, whether they are true pathogens or contaminants, the severity of sepsis, and the underlying diseases [ 1 , 2 , 3 , 4 , 5 ]. Previous studies have shown that clinically significant pathogens were detected within 3 days of incubation using continuous monitoring automated blood culture instruments, missing 3–5%, and raised the question whether 3 days are enough for blood culture incubation [ 2 , 5 , 6 , 7

), hepatic blood volume (BV), time to peak (TTP), permeability (PMB), arterial liver perfusion (ALP), portal venous perfusion (PVP) and hepatic perfusion index (HPI)) in target lesion, selectiveness of TACE, the use of microcatheter, the use of ConeBeam CT technology, type and size of embolization particles, the dose of chemotherapeutic (doxorubicin), number of DEBTACE procedures, response to treatment according to mRECIST criteria and survival. CTPI protocol CTPI was performed by using a 64-slice dual-source CT (Siemens Medical Systems®, Erlangen, Germany). The scan


Objective. Thrombotic thrombocytopenic purpura (TTP) is a rare disease characterized by microangiopathic hemolytic anemia, thrombocytopenic purpura, neurologic abnormalities, fever, and renal insufficiency. The association or co-existence of thyrotoxicosis or antithyroid drugs with TTP has not been previously reported.

Subject and Results. Herein, we present a 54-year-old female patient newly diagnosed with toxic multinodular goiter accompanying with TTP, possibly triggered by either thyrotoxicosis or antithyroid drugs.

Conclusions. The present report is the first in the literature to demonstrate the co-existence of these two diseases and the use of plasma exchange as a modality to treat both conditions.

progression (TTP) and OS in MM, led us to further investigate their potential role in baseline genetic risk of MM development. Our aim was to investigate selected MMP polymorphisms as baseline risk predictors in MM development in combination with other well known risk factors, such as asbestos exposure. Patients and methods Patients Patients with histologically confirmed pleural or peritoneal mesothelioma diagnosed and treated between 2007 and 2016 were included in this retrospective study. Patients were diagnosed mostly at the University Clinic Golnik and at the


A common approach to demands for lawful access to encrypted data is to allow a trusted third party (TTP) to gain access to private data. However, there is no way to verify that this trust is well placed as the TTP may open all messages indiscriminately. Moreover, existing approaches do not scale well when, in addition to the content of the conversation, one wishes to hide one’s identity. Given the importance of metadata this is a major problem. We propose a new approach in which users can retroactively verify cryptographically whether they were wiretapped. As a case study, we propose a new signature scheme that can act as an accountable replacement for group signatures, accountable forward and backward tracing signatures.


Background: Platinum-paclitaxel and platinum-gemcitabine are commonly used first-line chemotherapies for advanced non-small-cell lung cancer (NSCLC). Currently, there is no established biomarker predicting the treatment outcomes of these two regimens. Previous studies have suggested that p53 expression might determine the response to platinum compounds and gemcitabine, but not paclitaxel. We hypothesized that p53 overexpression would predict a worse response to platinum-gemcitabine than to platinum-paclitaxel in patients with advanced NCSLC.

Objective: To investigate whether tumor p53 expression would be able to predict the treatment outcome of these two chemotherapy regimens in advanced NSCLC patients.

Methods: We identified patients with advanced NSCLC who had been treated with either platinum-gemcitabine or platinum-paclitaxel as first-line chemotherapy at King Chulalongkorn Memorial Hospital. We obtained the corresponding archived tissue samples and performed immunohistochemical staining to determine the p53 expression in tumor tissues. We then compared the response rates and time to progression (TTP) between two regimens and p53 expression statuses.

Results: Of the 76 advanced NSCLC patients, we identified 40 (52.6%) patients with p53 overexpression, in which we showed better treatment outcomes with platinum-paclitaxel than with platinum-gemcitabine: the response rates were 42.1% vs 14.3% (p = 0.053) and TTPs were 5.3 [95%CI, 4.3-6.3] months vs 3.3 [95%CI, 1.3-5.2] months (p = 0.067). In the platinum-gemcitabine group, the response rate and TTP were better in normal expression of p53 subgroup compared to p53-overexpression subgroup (response rate 47.4% vs 14.3%, p = 0.026 and TTP 5.0 [95%CI, 4.4-5.5] months vs 3.3 [95%CI, 1.3-5.2] months, p = 0.062). These differences were not found in the platinum-paclitaxel group.

Conclusion: Our findings suggest that p53 expression is a potential predictive marker for the response to platinum-gemcitabine in advanced NSCLC. Consequently, platinum-paclitaxel would be favored over platinumgemcitabine in patients with p53 overexpression.